Summary of "Drug discovery and development process"

Main ideas & lessons conveyed

Patient focus: The drug development process is framed around helping patients overcome disease and improving quality of life.
Goal of the development process: Ensure that innovative new medicines are effective, safe, and available for patients as quickly as possible.
Target discovery is foundational: Finding the right biological targets (often proteins) associated with disease—either in the patient or in disease-causing microorganisms—is critical.
Move from single targets to pathways/networks:
- Disease biology can involve networks of proteins rather than a single protein.
- A single protein can transmit signals to multiple proteins across one or more pathways.
- Understanding pathway mechanisms and interactions helps identify the most appropriate drug target.
Unmet medical needs drive priorities: The company aligns target discovery priorities with both scientific knowledge and the desire to address unmet medical needs.
Early discovery produces “hits,” refined into candidates:
- Methods such as high-throughput screening and computer-based design are used to find compounds/biologics that bind to targets.
- A promising binder that modulates the target as expected is called a hit.
- Hits are refined to improve safety and effectiveness, becoming a drug candidate.
Length and cost of drug development: Bringing one new drug to market typically takes about 14 years and costs around $2 billion (US).
Many attempts, few successes: Of 10,000+ hits tested early, only one may ultimately progress to a market-approved drug.
Preclinical diligence and pharmacokinetics:
- Candidates undergo extensive experiments to confirm they are safe and have suitable pharmacokinetic properties (e.g., absorption and metabolism in the human body).
- Animal studies are described as important for understanding complex disease mechanisms.
Animal use with welfare commitments: The process includes:
- Compliance with government and regulatory requirements for animal testing before human trials.
- A commitment to refine, reduce, and replace animal use where possible and maintain high standards of animal welfare.
Clinical trials happen in phases:
- Phase 1: safety and pharmacokinetics in healthy volunteers.
- Phase 2: efficacy and dosing in ~100–250 patients.
- Proof-of-concept (POC): early mixed Phase 1/2 style studies to confirm the drug affects the target as intended.
- Phase 3: confirm effectiveness in ~1,000–3,000+ patients, compare against standards, and monitor side effects.
Regulatory registration and dossier submission:
- A registration dossier containing clinical efficacy and safety data is submitted for approval.
- Dossiers are adapted by region/country to meet specific health authority requirements.
Post-approval (Phase 4) and ongoing safety monitoring:
- After launch: mandatory drug safety monitoring, periodic updates, and annual reports.
- Phase 4 trials gather additional data not collected in Phase 3, including further benefit/risk, safety/efficacy, and sometimes pharmacoeconomic information.

Methodology / step-by-step process (detailed bullets)

1) Target discovery

Identify disease-relevant targets
- Targets are usually proteins in the patient or proteins in microorganisms causing the disease.
Confirm biological role
- Determine which proteins are relevant and validate their role in disease.
Use pathway/network understanding
- Study cellular protein networks/pathways rather than one isolated protein.
- Use this to determine how pathways work together and influence function.
Select priorities
- Combine pathway/mechanism knowledge with the goal of addressing unmet medical needs.

2) Hit discovery (finding binders/modulators)

Use methods such as:
- High-throughput screening
- Computer-based design
Find chemical compounds or biologics that bind to the target.
Define a hit
- A compound that modulates the target in an expected way that could alter the disease.

3) Hit-to-candidate optimization

Refine hits to improve:
- Safety
- Effectiveness
Produce a drug candidate.

4) Preclinical testing and safety assessment

Conduct experiments (with “extraordinary diligence”) to:
- Ensure safety for eventual human testing
- Confirm required pharmacokinetic properties (e.g., absorption/metabolism)
Use animal studies because:
- Complex disease mechanisms can often require in vivo understanding.
Follow regulations requiring animal testing prior to human trials.
Maintain animal welfare commitments:
- Refine, reduce, replace animal use as possible while meeting standards.

5) Clinical trials (phased)

Phase 1
- Test in healthy volunteers
- Objectives: safety and pharmacokinetics
Phase 2
- Treat ~100–250 patients with the disease
- Objectives:
  - Evaluate efficacy
  - Determine optimal dose
  - Assess safety and side effects (which may differ from Phase 1)
Proof of concept (POC) trials
- Often a mix of Phase 1 and Phase 2 approaches
- Treat a well-defined patient group
- Goal: early indication that the drug affects the target as intended and improves disease outcomes
- Purpose: enable faster decision-making about investing resources in effective/safe compounds
Phase 3
- Recruit ~1,000–3,000+ patients
- Objectives:
  - Confirm the new drug’s effectiveness
  - Monitor side effects
  - Compare with established treatments
  - Collect additional information for appropriate use

6) Regulatory approval and market launch

Compile clinical evidence into a registration dossier
- Includes efficacy and safety data
Customize dossier for different countries/regions to meet local health authority requirements.
After approval and launch:
- Continue ongoing compliance and monitoring.

7) Post-authorization monitoring (Phase 4 and beyond)

Perform mandatory drug safety monitoring
Provide:
- Safety updates
- Annual reports
- Additional required information at defined intervals
Initiate Phase 4 trials to collect:
- Additional efficacy/safety
- Further benefit-risk details
- Possibly pharmacoeconomic information

Speakers / sources featured

Speaker/source named in the subtitles: Novaris / Novartis (company referenced; “Novaris” appears to be an auto-caption error for Novartis).
Website source mentioned: www.clinicaltrials.gov
Other named sources: government and regulatory authorities, health authorities (not individually named).